The purpose of this study was to compare the relative risk of second malignancies in a cohort of patients with hairy cell leukemia (HCL) against the normal population.
Potential effects of type of treatment and duration of follow-up and the site distribution of cancer were also examined.
Between 1976 and 1996,117 patients were diagnosed with HCL in British Columbia who were referred to the British Columbia Cancer Agency (BCCA) for treatment.
All additional malignancies were traced using a provincial population-based cancer registry and follow-up records from the BCCA.
There were 90 men and 27 women.
Median age at diagnosis was 53 years.
The median follow-up time was 68 months.
Twenty-three patients underwent primary splenectomy, 65 received interferon alpha, 24 deoxycoformycin, and 67 cladribine (2-chlorodeoxyadenosine).
Thirty-six patients had an additional malignancy (30.7%) with a total of 44 tumors.
Six patients (5.1%) had two or more malignancies.
Twenty-five patients had malignancies diagnosed after HCL (21.3%), three concurrent with HCL (2.6%), and 12 preceding HCL (10.2%). Second tumors (n=28 tumors) occurred at a median of 40 months after HCL (range, 3 to 167).
The relative rate (RR) of second malignancy among men and women was 2.91 (P<. 001) and 1.65 (P=23), respectively, compared with age and secular trend-matched controls.
There were eight prostate cancers, nine nonmelanoma skin cancers, two lung cancers, and four gastrointestinal adenocarcinomas. (...)
Mots-clés Pascal : Leucémie lymphohistiocytaire, Facteur risque, Epidémiologie, Second cancer, Splénectomie, Traitement, Chimiothérapie, Purine nucléoside, Analogue, Anticancéreux, Interféron, Immunothérapie, Colombie britannique, Canada, Amérique du Nord, Amérique, Etude cohorte, Etude longitudinale, Homme, Chronique, Cytokine, Hémopathie maligne, Lymphoprolifératif syndrome, Tumeur maligne, Chirurgie
Mots-clés Pascal anglais : Hairy cell leukemia, Risk factor, Epidemiology, Second cancer, Splenectomy, Treatment, Chemotherapy, Purine nucleoside, Analog, Antineoplastic agent, Interferon, Immunotherapy, British Columbia, Canada, North America, America, Cohort study, Follow up study, Human, Chronic, Cytokine, Malignant hemopathy, Lymphoproliferative syndrome, Malignant tumor, Surgery
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0444549
Code Inist : 002B19B. Création : 25/01/1999.